KPV

KPV is a tripeptide fragment (Lysine-Proline-Valine) derived from the C-terminal tail of α-melanocyte-stimulating hormone (α-MSH). It is studied primarily for anti-inflammatory properties in contexts including inflammatory bowel disease, skin inflammation, and wound healing. It is sold in the research-peptide market as a supportive peptide for gut and inflammatory issues.

KPV's anti-inflammatory effects are proposed to operate through multiple pathways: interaction with melanocortin receptors (though less potently than full α-MSH), modulation of NF-κB signaling, downregulation of pro-inflammatory cytokines (TNF-α, IL-6), and direct antimicrobial activity in some tissue contexts. Its small size (three amino acids) is unusual for a biologically-active peptide and may favor oral or topical delivery in some contexts.

Preclinical research spans roughly two decades, with animal and in-vitro models of IBD, psoriasis, and wound healing. Clinical research in humans is limited — small Phase 1/2 studies exist for inflammatory bowel contexts but have not advanced to Phase 3 or FDA approval.

Preclinical and early clinical research. No active Phase 3 development.

Not FDA approved. FDA Category 2 (September 2023). Feb 2026 HHS proposed removal. Research-use-only sales. Full regulatory timeline →

KPV has reasonable preclinical support for anti-inflammatory activity, but the human clinical evidence is thin and the biohacker marketing for gut-health benefits outruns the peer-reviewed data. The compound's small size makes stability and bioavailability in real-world use variable.

• α-MSH fragments anti-inflammatory review →
• KPV in IBD animal models →